apricus wealth LLC Has $2.12 Million Stock Position in Novartis AG (NYSE:NVS)

apricus wealth LLC increased its position in Novartis AG (NYSE:NVS) by 2.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 21,813 shares of the company’s stock after acquiring an additional 600 shares during the period. apricus wealth LLC’s holdings in Novartis were worth $2,123,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC acquired a new position in shares of Novartis during the 3rd quarter worth about $28,000. Fortitude Family Office LLC grew its position in shares of Novartis by 503.8% during the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after buying an additional 267 shares during the period. Clean Yield Group acquired a new position in shares of Novartis during the 3rd quarter worth about $43,000. Brooklyn Investment Group acquired a new position in shares of Novartis during the 4th quarter worth about $55,000. Finally, Beaird Harris Wealth Management LLC grew its position in shares of Novartis by 280.5% during the 3rd quarter. Beaird Harris Wealth Management LLC now owns 704 shares of the company’s stock worth $81,000 after buying an additional 519 shares during the period. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on NVS. HSBC lowered Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Finally, BMO Capital Markets boosted their price objective on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Trading Down 0.1 %

NYSE NVS opened at $99.93 on Friday. The company has a market cap of $204.25 billion, a PE ratio of 11.61, a PEG ratio of 1.42 and a beta of 0.57. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The stock has a 50 day moving average of $100.15 and a 200-day moving average of $108.75.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.94 by $0.12. The company had revenue of $12.82 billion during the quarter, compared to the consensus estimate of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same quarter in the prior year, the firm posted $1.74 EPS. On average, equities research analysts anticipate that Novartis AG will post 7.62 EPS for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.